|Drug Name||GPCR-targeted Project 015|
A first-in-class recombinant antibody targeting Frizzled 8 (Fzd8) receptor is being developed for the treatment of solid tumors. It is expected that the candidate may be developed in combination with standard chemotherapy and targeted therapy.
|Target||Frizzled 8 (FZD8)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||Frizzled 8 modulators|
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.